Abstract:Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and is a major cause of stroke and morbidity. Recent genome-wide association studies have shown that paired-like homeodomain transcription factor 2 (Pitx2) to be strongly associated with AF. However, the mechanisms underlying Pitx2 modulated arrhythmogenesis and variable effectiveness of antiarrhythmic drugs (AADs) in patients in the presence or absence of impaired Pitx2 expression remain unclear. We have developed multi-scale computer models, ranging from a single cell to tissue level, to mimic control and Pitx2-knockout atria by incorporating recent experimental data on Pitx2-induced electrical and structural remodeling in humans, as well as the effects of AADs. The key findings of this study are twofold. We have demonstrated that shortened action potential duration, slow conduction and triggered activity occur due to electrical and structural remodelling under Pitx2 deficiency conditions. Notably, the elevated function of calcium transport ATPase increases sarcoplasmic reticulum Ca<sup>2+</sup> concentration, thereby enhancing susceptibility to triggered activity. Furthermore, heterogeneity is further elevated due to Pitx2 deficiency: 1) Electrical heterogeneity between left and right atria increases; and 2) Increased fibrosis and decreased cell-cell coupling due to structural remodelling slow electrical propagation and provide obstacles to attract re-entry, facilitating the initiation of re-entrant circuits. Secondly, our study suggests that flecainide has antiarrhythmic effects on AF due to impaired Pitx2 by preventing spontaneous calcium release and increasing wavelength. Furthermore, our study suggests that Na<sup>+</sup> channel effects alone are insufficient to explain the efficacy of flecainide. Our study may provide the mechanisms underlying Pitx2-induced AF and possible explanation behind the AAD effects of flecainide in patients with Pitx2 deficiency.Atrial fibrillation (AF) is an abnormal heart rhythm that can lead to stroke and death. Recent studies have uncovered that AF-associated risk variants are adjacent to the Pitx2 locus, furthermore, the have demonstrated that AF patients with these variants respond better to certain antiarrhythmic drugs (AADs). However, the mechanisms underlying Pitx2 modulated arrhythmogenesis and variable effectiveness of AADs remain unclear. To untangle this issue, we have developed multi-scale computer models, ranging from single cell to tissue level, to mimic control and the Pitx2-knockout atria by incorporating experimental data on Pitx2-induced electrical and structural remodelling, as well as the effects of class I ADDs (flecainide). We discovered that removal of Pitx2 caused AF characterized by focal beats and re-entrant waves. It was found that these abnormalities can be attributed to triggered beats, action potential duration shortening and slow conduction arising from Pitx2-induced remodelling. Interestingly, these Pitx2-induced AF can be suppressed in the presence of class I AADs such as flecainide. Our simulations revealed that flecainide prevents triggered beats by blocking the function of ryanodine receptors and that flecainide can terminate re-entrant waves by prolonging action potential duration due to its actions on potassium channels.

Flecainide induces a sustained countercurrent dependent effect on RyR2 in permeabilized WT ventricular myocytes but not in intact cells

Loss of Luminal Ca 2+ Activation in the Cardiac Ryanodine Receptor is Associated with Ventricular Fibrillation and Sudden Death

Enhanced Store Overload–Induced Ca 2+ Release and Channel Sensitivity to Luminal Ca 2+ Activation Are Common Defects of RyR2 Mutations Linked to Ventricular Tachycardia and Sudden Death

Characterization of a Novel Mutation in the Cardiac Ryanodine Receptor That Results in Catecholaminergic Polymorphic Ventricular Tachycardia

RyR 2 Mutations Linked to Ventricular Tachycardia and Sudden Death Reduce the Threshold for Store-Overload-induced Ca 2 Release ( SOICR )

The Different Effects of Flecainide on the Excitability of Myocardial Cells in Rabbit Left Ventricular

Effect of flecainide on atrial fibrillatory rate in a large animal model with induced atrial fibrillation

Safety of flecainide

A gain of function ryanodine receptor 2 mutation (R1760W-RyR2) in catecholaminergic polymorphic ventricular tachycardia

Flecainide Toxicity On An Existing Long QT Requiring Mechanical Circulatory Support

In silico investigation of the mechanisms underlying atrial fibrillation due to impaired Pitx2

Inhibitors of Intracellular RyR2 Calcium Release Channels as Therapeutic Agents in Arrhythmogenic Heart Diseases

Disrupting Ca2+ Waves, but Not Ca2+ Leak, Protects Against Cardiac Arrhythmia

Kir2.1 mutations differentially increase the risk of flecainide proarrhythmia in Andersen Tawil Syndrome

Sarcoplasmic Reticulum Ca2+ Release Channel Ryanodine Receptor (ryr2) Plays a Crucial Role in Aconitine-Induced Arrhythmias

Sustained subthreshold-for-twitch depolarization in rat single ventricular myocytes causes sustained calcium channel activation and sarcoplasmic reticulum calcium release

Electrophysiological Mechanism of Catestatin Antiarrhythmia: Enhancement of Ito, IK, and IK1 and Inhibition of ICa-L in Rat Ventricular Myocytes

Sensitized Signalling Between L-type Ca2+channels and Ryanodine Receptors in the Absence or Inhibition of FKBP12.6 in Cardiomyocytes

Single Rat Ventricular Cells

Ischaemia-induced loss or reversal of the effects of the class I antiarrhythmic drugs on vulnerability to fibrillation

Selective inhibition of late sodium current suppresses ventricular tachycardia and fibrillation in intact rat hearts